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In addition to 17-estradiol binding, estrogen receptor (ER)
transcriptional activity could be controlled by intracellular
kinase signalingpathways activatedbygrowth factors. In this
reportwepresent evidence suggesting that glycogen synthase
kinase 3 (GSK3), aneffectorkinaseof thephosphatidylinositol
3-kinase (PI3K) pathway, may affect ER activity in N2a neu-
roblastoma cells. LiCl, sodium valproate, and SB415286, three
inhibitors of GSK3, dose-dependently blocked ER-mediated
transcription. In contrast, overexpression of wild-type GSK3,
but not of a mutant inactive form, increased ER-dependent
gene expression. Pharmacological or genetic inhibition of the
PI3K/Akt pathway,whose activity is inversely correlatedwith
that of GSK3, increased ER-mediated transcription, and this
effect was blocked by GSK3 inhibitors. As in other cell types,
IGF-I increased ER activity in absence of estradiol by a
mechanism independent of PI3K. In contrast, IGF-I decreased
ER activity in the presence of estradiol, and this effect was
mediated by PI3K. We also observed a regulated interaction
between -catenin, one of themain GSK3 nuclear targets, and
ER. Transfection with a nondegradable mutant of -catenin
blocked the increase in ER transcriptional activity induced
by the PI3K inhibitor wortmannin, suggesting a role for
-catenin in estrogen signaling. In addition, we investigated
the regulation of ER protein levels as a potential mechanism
for its regulation by the PI3K/GSK3 pathway; GSK3 blockade
increased ER protein stability, whereas PI3K inhibition de-
creased it. In summary, our findings suggest that ER-depen-
dent gene expression in N2a cells is controlled by the PI3K/
Akt/GSK3 signaling pathway. (Endocrinology 147: 3027–3039,
2006)
THE OVARIAN HORMONE 17-estradiol (E2) exertsprofound effects on the physiology and pathology of
the central nervous system (CNS) (1). In the brain, E2 is able
to regulate the expression of a wide subset of genes and the
activity of multiple signaling systems. The main biological
actions of E2 are mediated by its binding to its cellular
receptors that belong to the superfamily of nuclear receptors
(2). The two identified subtypes of estrogen receptors (ERs),
ER and ER, are abundantly expressed in the brain (3).
These are transcription factors that upon ligand binding,
directly bind to DNA in the promoter regions of many genes
in which an estrogen response element (ERE) exists. ERs can
be divided into six (A–F) functional and physical domains,
which encode the regions required for hormone binding (E),
nuclear localization (D), or DNA binding (C; Fig. 1A). ERs
have two separate transactivation domains: activation func-
tion 1 (AF1) localized in domain A/B, and AF2 localized in
domain E (4). The ability of ERs to induce changes in gene
expression is mediated by their interaction with members of
the mRNA synthesis machinery, which include coactivators
and corepressors (5).
In addition to E2 binding, ER transcriptional activity can
be regulated by ligand-independent mechanisms (6). Intra-
cellular kinase signaling pathways, activated by extracellular
growth or trophic factors, regulate the ability of ERs to pro-
mote changes in gene expression. IGF-I is one of the extra-
cellular regulators of these kinase pathways that has been
shown to promote ERE-dependent transcription (7, 8). In
addition, IGF-I has been shown to have a wide interdepen-
dence with estrogen in the promotion of its multiple effects,
in particular in the CNS (9–13). The functional relevance of
this cross-talk between IGF-I and estrogen in the CNS is quite
well established, but the mechanisms are only beginning to
be understood (14).
Two signaling pathways regulated by IGF-I and other
extracellular factors are the MAPK and the phosphatidyl-
inositol 3-kinase (PI3K) pathways (15). IGF-I, epidermal
growth factor, nerve growth factor, and brain-derived neu-
rotropic factor activate both intracellular cascades by binding
to their cognate membrane receptors. Different members of
MAPK and PI3K signaling systems, i.e. Akt and ERK, phos-
phorylate and positively regulate the transactivation prop-
erties of ER (16, 17). The AF1 in the N-terminal domain of
ER is essential for growth factor activation of its transcrip-
tional activity (16). However, direct phosphorylation is not
the only way in which intracellular kinases modify ER ac-
tivity. ER coactivators of the p160 family, such as steroid
receptor coactivator 1, have also been shown to be targets of
the MAPK/ERK pathway (18).
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Glycogen synthase kinase 3 (GSK3) is a component of the
PI3K signaling pathway. It is a serine/threonine kinase
widely expressed in mammalian tissues that has two iso-
forms, GSK3 and GSK3 (19). It has critical roles during
development, and in adult organisms regulates glycogen and
lipid metabolism, cytoskeletal dynamics, and apoptosis (19).
GSK3, unlike most kinases, has a high level of activity in
resting cells that is negatively regulated by phosphorylation
of the serine residue in the N-terminal region of the molecule
(serine 11 for GSK3 and serine 9 for GSK3). This phos-
phorylation is effected, upon hormonal or growth factor
stimulation, by intracellular kinases such as Akt, protein
kinase A, and p70S6 kinase (20). Despite the specificity that
its name suggests, GSK3 has a wide variety of targets in
intracellular signaling systems, including many transcrip-
tion factors and nuclear proteins such as activation protein
1, cAMP response element-binding protein, nuclear factor-
B, and -catenin (19). Some of these proteins are directly
phosphorylated by GSK3, such as -catenin or c-Jun, a com-
ponent of activation protein 1 transcription factor. Other
molecules, such as nuclear factor-B, are not direct targets of
GSK3 phosphorylation, but they are regulated by changes in
its activity (21). In the present study using N2a neuroblas-
toma cells as a model, we investigated the role of the PI3K/
Akt/GSK3 signaling pathway in the control of estrogen re-
ceptor-mediated transcription in neuronal cells.
Materials and Methods
Cell culture
Neuro-2a (N2a) neuroblastoma cells (American Type Culture Col-
lection, Manassas, VA; CCL-131) were gifts from Dr. M. A. Arevalo
(Instituto Cajal, Madrid, Spain). They were cultured in DMEM/Ham’s
F-12 medium supplemented with 10% fetal calf serum (FCS; Invitrogen
Life Technologies, Inc., Barcelona, Spain). For experimental procedures,
they were plated in medium supplemented with 10% charcoal- and
dextran-treated FCS (C/D FCS; HyClone, Logan, UT) in six- and 12-well
plates (Falcon, BD Biosciences, Madrid, Spain). The same procedure was
used to culture HEK293 and HT22 cell lines. The cells used in the
experiments presented in this report were cultured for no more than 10
passages.
Materials and expression plasmids
The inhibitors LY294002, PD98059, MG132, SH-6, and wortmannin
were purchased from Calbiochem (Merck, Nottingham, UK). SB415286
was obtained from Tocris (Avonmouth, UK). E2, lithium chloride, and
valproic acid (sodium salt) were obtained from Sigma-Aldrich Corp. (St.
Louis, MO). ICI182780 was obtained from Zeneca Pharmaceuticals
(Cheshire, UK). The subtype-specific estrogen receptor agonists propy-
lpyrazole triol (PPT) and 2,3-bis(4-hydroxyphenyl) proprionitrile (DPN)
were purchased from Tocris and were predissolved, as was E2, in
FIG. 1. ER expressed by N2a cells is controlled by intracellular kinases. A, Mapping of the primers (PCR) and antibodies (Ab) used for PCR
andWestern blot analyses, respectively, of both subtypes of ERs (ER and ER) in N2a cells. B, cDNAs from N2a cells, mouse ovary, and HT22
cells were amplified using pairs of specific primers for ER, ER, and a constitutive gene (18S RNA). Transcript for ER is observed in N2a
cells and ovary. Transcript for ER is clearly seen in the ovary. InN2a cells, the level of ER transcript is very low, but detectable. ER transcripts
are not detected in HT22 cells. C, Protein extracts from N2a cells (20 g) were tested for the presence of ER and ER using specific antibodies
and compared with those in cell lysates obtained from HEK293 cells (HEK; 20 g), rat ovary (Ov; 50 g), or human ER-overexpressing N2a
cells (N2a hER; 1 g). ER was clearly detected in N2a cells and ovary extracts, but not in HEK293 cells. Recombinant ER was detected
in ER-transfected N2a cells, whereas endogenous ER was only detected in nontransfected N2a cells (and not in transfected cells due to the
different amount of protein loaded in each case). D, After transfection with the reporter plasmids (pTA-ERE-SEAP and pCMV-Gal), cells were
incubated with 1 nM E2 (ER and ER agonist), 10 nM PPT (ER agonist), 10 nM DPN (ER agonist), and 10 nM PPT plus 10 nM DPN.
ER-dependent gene expression was quantified by measuring SEAP activity and normalized for transfection efficiency. Data are expressed as
the mean  SEM fold induction detected with each compound compared with that in control cells (C; vehicle treated). E2 and the ER-specific
agonist PPT increased the activity of the SEAP reporter gene, whereas DPN had no effect. *, P  0.05 vs. control values. E, The E2 induction
of ER dependent reporter activity was quantified in the presence of the estrogen receptor antagonist ICI182780 (ICI; 100 nM) or inhibitors of
intracellular kinases, PD98059 (PD; 25 M), PP2 (1 M), LY294002 (LY; 25 M), and LiCl (10 mM), that were added to the culture medium 45
min before E2 treatment. Data are expressed as described inD. The ER antagonist ICI182780 completely blocked the expression of the reporter
gene induced by E2. The MAPK inhibitor PD98059 and the Src inhibitor PP2 had no effect. In contrast, the PI3K inhibitor LY294002 and
the GSK3 inhibitor LiCl significantly decreased the expression of the reporter gene induced by E2. *, P  0.05 vs. E2 alone.
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dimethylsulfoxide. Control cultures received similar amounts of solvent
(vehicle). IGF-I was purchased from Gro-Pep (Adelaide, Australia). The
polyclonal antibodies against mouse ER (MC20) were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). ER antibody (ZP8)
was purchased from Zymed Laboratories (Invitrogen Life Technologies,
Inc., Barcelona, Spain). The monoclonal antibody against human ER
(AER611) used for Western blotting and immunoprecipitation protocols
was purchased from NeoMarkers (Fremont, CA). The anti-GSK3 and
-catenin monoclonal antibodies were purchased from BD Transduction
Laboratories (Madrid, Spain). Anti-p85 antiserum was a gift from Dr. S.
Pons (Instituto de Investigaciones Biome´dicas de Barcelona, Barcelona,
Spain). M2 antibody, raised against the Flag tag sequence, was pur-
chased from Sigma-Aldrich Corp. III tubulin monoclonal antibody was
purchased from Promega Corp. (Barcelona, Spain), and the antibodies
against phosphorylated forms of GSK3 and Akt were obtained from Cell
Signaling Technology (Beverly, MA).
Constructs of the secreted alkaline phosphatase (SEAP) reporter gene
controlled by a minimal promoter and ERE or retinoic acid (RA) re-
sponse element (RARE; pERE-SEAP and pRARE-SEAP, respectively)
were purchased from BD Biosciences. The expression plasmids for rat
GSK3 (22) and -catenin (23) forms were gifts from Dr. F. Wandosell
(Centro de Biologı´a Molecular, Madrid, Spain). The human ER ex-
pression plasmid was obtained from Dr. P. Auricchio (Dipartimento di
Patologia Generale, Universita di Napoli, Naples, Italy); pHEGO, en-
coding human ER, was a gift from Dr. P. Chambon (Institut de Ge´-
ne´tique et de Biologie Mole´culaire et Cellulaire, Strasbourg, France).
Both forms of the murine p85 subunit of PI3K, wild-type p85 (p85wt) and
p85110 (both fused to a Flag epitope) (24), and of human IGF-I receptor
(IGF-IR), the wt form (IGFIRwt) and a mutated form (IGFIR-KR) (25),
were gifts from Dr. S. Pons (Barcelona, Spain).
RT-PCR
Total RNA from N2a cells and mouse ovary were isolated with TRIzol
reagent (Invitrogen Life Technologies, Inc.). Two micrograms of total
RNA were used for a retro transcription reaction using Moloney’s mu-
rine leukemia virus retrotranscriptase (Promega Corp.). The products of
these reactions were used as substrates for PCR, using pairs of primers
specific for murine ER (accession no. M38651) or ER (accession no.
AJ000220) (26). The sequences of these primers were as follows: ER
sense, CAAAGCTGGCCTGACTCTGC; ER antisense, CCTCTGCTTC-
CGGGGGTATGTA; ER sense, GTCCTGCTGTGATGAACTAC; and
ER antisense, CCCTCTTGGTGCTTGGACT. For both ERs, the ampli-
fied region spanned different exons that corresponded to the C-terminal
region of the receptor in the case of ER (nucleotides 1682–1981) and to
the N-terminal region (nucleotides 10–282) in the case of ER (Fig. 1A).
The primers used for amplification of 18S ribosomal RNA were pur-
chased from Ambion, Inc. (Austin, TX), and produced a fragment of 488
nucleotides. The products of PCR were resolved in 1.5% agarose gels and
stained with ethidium bromide.
Transient expression and reporter gene experiments
We measured the estrogen dose- and time-dependent responses of
ERE reporter constructs to identify the best conditions for studying
ER-mediated transcription in N2a cells (data not shown). We cotrans-
fected a plasmid expressing the -galactosidase gene under the control
of a constitutive promoter [cytomegalovirus--galactosidase promoter
(pCMV-Gal)] to normalize the values of SEAP activity to transfection
efficiency and detect changes in basic transcriptional machinery. For
reporter gene experiments, cells were plated in 12-well plates with 10%
C/D FCS 24 h before overnight transfection with FuGene (Roche, Mann-
heim, Germany). Normally, the transfection mixture included 100–200
ng pERE-SEAP (or pRARE-SEAP) and 100 ng pCMV-Gal. When
needed, overexpression plasmids for GSK3, IGF-IR, p85, or -catenin or
the empty vector (pcDNA3; Invitrogen Life Technologies, Inc.) were
added to this mixture (200 ng/well). After transfection, the medium was
changed to 2% C/D FCS; 1 d later, cells were subjected to the experi-
mental treatments for 24 h. Culture supernatants were collected for
determining SEAP activity using a luminescent assay (BD Biosciences),
and cell lysates were assayed for Gal activity (27). Data are presented
as the fold induction of reporter activity in each experiment. For Western
blotting and immunoprecipitation purposes, cells were cultured in
35-mm diameter wells in medium containing 10% C/D FCS. When
needed, they were transfected with overexpressing plasmids (0.2 g/
well). All treatments were applied after incubation for at least 24 h in
culture medium with reduced serum (2% C/D FCS).
Immunoprecipitation and Western blot experiments
Cells were washed once with PBS and lysed in a buffer containing 150
mm NaCl, 20 mm Tris HCl, 10% glycerol, 5 mm EDTA, and 1% Nonidet
P-40 (Roche) supplemented with protease and phosphatase inhibitors
(50g/ml phenylmethylsulfonylfluoride, 10g/ml aprotinin, 25g/ml
leupeptin, and 100 nm orthovanadate; all from Sigma-Aldrich Corp.).
Homogenates were briefly sonicated, solubilized for 30 min on ice, and
centrifuged at 21,000  g for 10 min. The protein content of the super-
natant was measured with a modified Bradford assay (Bio-Rad Labo-
ratories, Munich, Germany). Aliquots containing 300 g protein were
subjected to immunoprecipitation using specific antibodies. The im-
mune complexes were adsorbed and precipitated using preequilibrated
protein A-Sepharose beads (Amersham Biosciences, Little Chalfont,
UK), washed three times with lysis buffer, and denatured by boiling for
5 min in sample buffer [13 mm Tris (pH 6.8), 10% glycerol, 2% sodium
dodecyl sulfate, 0.1 m dithiothreitol, and 0.002% bromophenol blue]. For
analysis of ER stability, cells were lysed in a buffer containing 10 mm
Tris (pH 7), 10 mm NaCl, 3 mm MgCl2, 0.05% Nonidet P-40, and 1 mm
EGTA, supplemented with protease and phosphatase inhibitors. Cell
lysates were centrifuged at 1000  g for 10 min at 4 C to obtain the
cytosolic fraction. The immunoprecipitates, cellular lysates, or fractions
(10 g) were resolved by SDS-PAGE in a Mini-Protean system (Bio-Rad
Laboratories) and transferred to nitrocellulose membranes where spe-
cific proteins where immunodetected using an enhanced chemilumi-
nescence system (ECL, Amersham Biosciences). Films were analyzed
using Image J software (developed at the National Institutes of Health
and available on the internet at http://rsb.info.nih.gov/ij/). The density
of each band was normalized to its respective loading control and
represented as a percentage of the control value (cultures treated with
vehicle). When needed, membranes were stripped using a stripping
buffer provided by Chemicon International (Temecula, CA).
Immunofluorescence
For immunofluorescence analysis, cells were grown on gelatin-
treated coverslips. After washing twice with PBS, they were fixed with
4% paraformaldehyde for 15 min at room temperature, washed again
with PBS, and incubated overnight at4 C with the primary antibodies
[anti-ER and AER611 (NeoMarkers, Fremont, CA), diluted 1:250; anti-
GSK3 and anti--catenin (BD Transduction Laboratories), diluted
1:500], a solution of 0.1% Triton X-100, 0.1% BSA, and 3% normal goat
serum. The coverslips were washed extensively with PBS and incubated
with secondary antibodies conjugated with Alexa Red 568 or Alexa
Green 488 (both diluted 1:1000; Molecular Probes, Eugene, OR) for 2 h
at room temperature. They were mounted onto glass slides using
Mobiol-based mounting medium and examined using a confocal mi-
croscope (Leica, Heidelberg, Germany).
Statistical analysis
Reporter experiments were repeated at least three times. For Western
blots, at least three different experiments were quantitatively analyzed.
One-way ANOVA followed by post hoc analysis with the Bonferroni test,
unless otherwise specified, were used to determine statistically signif-
icant differences among three or more groups. P  0.05 was adopted as
the threshold of statistical significance. Data are represented as the
mean  sem.
Results
Activity of functional ER expressed in N2a cells is
controlled by inhibitors of intracellular kinases
We performed RT-PCR, Western blot, and reporter gene-
based analysis of N2a cells to assess whether they express
functional ERs. Using primers directed against different ex-
ons of the C-terminal region of ER and the N-terminal
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region of ER, we detected transcripts for both subtypes of
ER (Fig. 1, A and B) in N2a cells and ovary, but not in HT22
cells. The level of ER transcript was very low, but detect-
able, in N2a cells. The amplified fragments had the correct
size, as expected by analysis of the published sequences for
both murine receptors (see Materials and Methods). For West-
ern blotting experiments, we used two different antibodies,
one directed against ER (MC20) and one directed against
ER (Z8P). We used HEK293 cells as a negative control for
the antibodies, because these cells do not express ERs. We
also used mouse ovary as a positive control for MC20 anti-
body and N2a cells overexpressing human ER as a positive
control for the Z8P antibody directed against ER. In N2a
cells, the MC20 antibody detected a band of approximately
67 kDa, the expected molecular mass for ER (Fig. 1C). This
band was also observed in mouse ovary together with an-
other band of slightly higher molecular mass. The ER an-
tibody detected both recombinant human ER and the en-
dogenous protein in N2a cells (Fig. 1C). ERs were not
detected in HEK293 cells (Fig. 1C).
We used an estrogen-sensitive reporter gene (pTA-ERE-
SEAP) to test the functionality of these endogenous recep-
tors. We compared the response evoked by E2, the natural
ligand for both subtypes of ERs, with the activation produced
by two compounds that bind to and activate only one sub-
type of receptor: PPT, a selective ligand for ER (28), and
DPN, a selective ligand for ER (29). Cells were stimulated
with 1 nm E2, 10 nm PPT, 10 nm DPN, or 10 nm PPT plus
10 nm DPN. PPT, the ER-specific agonist, increased the
activity of the SEAP reporter gene to a similar extent as E2,
whereas DPN did not have any effect (Fig. 1D). Simultaneous
treatment with both ligands, PPT and DPN, activated the
reporter to levels similar to those reached after E2
treatment.
Having established the functionality of the ERs expressed
by N2a cells, we screened several commonly used kinase
inhibitors for their abilities to modulate this estrogen-
responsive gene reporter assay. The inhibitors tested were
PD98059 for ERKs, PP2 for Src kinase, LY294002 for PI3K,
and lithium chloride (LiCl) for GSK3. We compared the
effects of these inhibitors with that of the blockade exerted
by ICI182780, a pure antagonist of classic ERs. N2a cells
were pretreated with these kinase inhibitors or ICI182780
for 45 min, then stimulated with 1 nm E2. SEAP activity
was determined 24 h later. As shown in Fig. 1E, ICI182780
completely blocked E2-induced expression of the reporter
gene, whereas MAPK and Src inhibitors had no effect. Both
LY294002 and LiCl significantly decreased E2-induced ex-
pression of the reporter gene (by 54% and 40%, respec-
tively). Although LY294002 has direct antiestrogenic activity
that could be responsible for the inhibitory effect seen in our
experiments (30), these results suggest a possible role of
PI3K/GSK3 in the control of ER-mediated transcription.
Effects of GSK3 inhibitors and GSK3 overexpression on the
activity of an estrogen-sensitive reporter construct
To investigate the role of GSK3 in the regulation of ER-
mediated transcription in N2a cells, we assessed the effects
of different concentrations of LiCl, sodium valproate, and
SB415286, three pharmacological inhibitors of GSK3 (31–33),
in the estrogen-responsive gene reporter assay. The three
inhibitors tested resulted in a decrease in ER-mediated tran-
scription in a dose-dependent manner (Fig. 2A). The inhib-
FIG. 2. GSK3 activity specifically controls ER-dependent gene ex-
pression in N2a cells. A, N2a cells were transfected with the ERE
reporter plasmid and treated with different concentrations of GSK3
inhibitors 45 min before E2 (1 nM) treatment. The concentrations
used were 2.5, 5, 10, and 20 mM for LiCl; 0.5, 2, and 3 mM for sodium
valproate; and 1, 5, 12.5, and 25 M for SB415286 (SB). The plots
represent the mean  SEM percentage of the total response (100%;
elicited by E2 alone). The three inhibitors tested resulted in a de-
crease in ER-mediated transcription in a dose-dependent manner. *,
P  0.05 vs. E2 alone. B, HEK293 cells were transfected with ER
and the ERE reporter plasmid. Cells were treated with the GSK3
inhibitors (Inhib) LiCl (10 mM), SB415286 (SB; 25 M), and sodium
valproate (Valp; 2 mM) 45 min before the addition of 1 nM E2.
ER-dependent gene expression was measured 24 h latter by quan-
tification of SEAP activity. Data are normalized to transfection effi-
ciency and are presented as the mean  SEM. In contrast to their
inhibitory effect on N2a cells, the GSK3 inhibitors LiCl and valproate
increased ER-mediated transcription in HEK293 cells, whereas
SB415286 was without effect. *, P  0.05 vs. E2 alone. C, N2a cells
were transfected with an RARE construct (pTA-RARE-SEAP). The
GSK3 inhibitors (Inhib) LiCl (10 mM), SB415286 (SB; 25 M), and
valproate (Valp; 2mM) were added 45min before treatment with 1 M
RA. Activation of the reporter gene was measured 24 h latter and is
represented, normalized, as the mean  SEM. In contrast to their
inhibitory effect on ER-mediated transcription, the GSK3 inhibitors
LiCl and SB415286 enhanced RA-mediated transcription, whereas
valproate was without effect. *, P  0.05 vs. RA alone. D, Cells were
cotransfected with pTA-ERE-SEAP and three different plasmids
(TF): an empty vector (Mock), thewt ratGSK3 (GSK3wt), or amutant,
kinase-inactive GSK3 (GSKR85). Twenty-four hours after transfec-
tion, cells were treated with E2 (1 nM) or its vehicle for an additional
24 h. SEAP activity was then quantified and normalized to transfec-
tion efficiency. The levels of GSK3 in each situation, as evaluated by
Western blotting, are shown below. The results are expressed as the
mean fold induction in each situation  SEM. Overexpression of
GSK3wt resulted in an increase in ER-mediated transcription. This
effect was not observed when the mutated inactive form of GSK3
(GSKR85) was overexpressed. *, P  0.05 vs. E2 response in the
GSK3wt-transfected group.
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itory effects of SB415286, LiCl, and valproate were also ob-
served when cells were stimulated with PPT, the ER-
specific agonist (not shown). To test whether GSK3 inhibition
affects ER activity in other cell types, we performed exper-
iments using HEK293 cells. Cells were transfected with ER
and pTA-ERE-SEAP and treated with E2 in the presence or
absence of GSK3 inhibitors. None of the GSK3 inhibitors
tested produced a decrease in ER-mediated transcription in
HEK293 cells (Fig. 2B). LiCl (10 mm) and valproate (3 mm)
increased the response of ER in HEK293 cells by 62% and
150%, respectively, whereas SB415285 showed no effect (Fig.
2B). In addition, we investigated whether the effect of GSK3
inhibition was similar to those of other members of the su-
perfamily of nuclear receptors to which ER belongs. We
tested the effects of LiCl, valproate, and SB415286 on the
activity of RA receptor (RAR) in N2a cells. For this experi-
ment, N2a cells were transfected with a reporter construct in
which SEAP reporter gene was under the control of RARE.
N2a express functional RAR whose activity is enhanced by
RA treatment. The GSK3 inhibitors, LiCl and SB415286, in-
creased the reporter response by 91% and 42%, respectively
(Fig. 2C). In contrast, valproate showed no effect on RAR-
mediated gene expression (Fig. 2C).
Because some GSK3 inhibitors used in this study may have
other targets, we decided to use genetic tools to demonstrate
GSK3 control of ER-mediated transcription in N2a cells. We
overexpressed two different forms of the kinase, the wt form
(GSK3wt) and a mutated, kinase-inactive form (GSK3R85)
(22). Although the levels achieved were not very high com-
pared with the control (Fig. 2D), the overexpression of
GSK3wt resulted in a significant increase (40%) in the re-
sponse of the reporter construct to the hormone. In contrast,
the enhancement of ER-mediated transcription was not ob-
served when the mutated, kinase-inactive form of GSK3
(GSK3R85) was transfected (Fig. 2D).
Effects of Akt and PI3K activities on ER-mediated
transcription in N2a cells
It is well established that one of the main signaling cas-
cades modulating GSK3 activity in mammalian cells is the
PI3K/Akt pathway (34–37). Therefore, we decided to inves-
tigate the role of GSK3 in PI3K control of ER-mediated tran-
scription in N2a cells. Because, as mentioned previously,
LY294002 has potential antiestrogenic effects due to its direct
inhibitory binding to ERs (30), we tested the effect of another
pharmacological PI3K inhibitor, wortmannin. Wortmannin
produced a decrease in the serine 9 phosphorylation of GSK3
(Fig. 3A) and induced a dose-dependent increase in ER-
mediated transcription (Fig. 3B). The two GSK3 inhibitors
tested, LiCl (Fig. 3B) and SB415286 (not shown), blocked the
effect of wortmannin on ER activity, suggesting that GSK3
mediates the effect of PI3K on ER-mediated transcription. In
addition, we performed experiments blocking the PI3K path-
way using a dominant-negative form of p85, the regulatory
subunit of this kinase. We used p85110, a truncated form of
p85 that lacks a small region implicated in the interaction
with p110, the catalytic subunit of PI3K (24). The expression
of wt and truncated forms of p85 was confirmed by Western
blotting using an antibody against the Flag tag carried by
both proteins (Fig. 3C). In both cases, the levels of expression
achieved were well over those of endogenous p85, as reveled
by Western blotting with the p85 antibody, which recognizes
endogenous and both transfected forms (Fig. 3C). The over-
expression of the mutated form resulted in a significant de-
crease in the serine 9 phosphorylation of GSK3 (Fig. 3C) and
a 45% increase in ER-mediated transcription compared with
cells overexpressing the wild-type form of p85 (Fig. 3D). We
consider it improbable, although it cannot be completely
excluded, that small differences in the expression of the wild-
type and truncated forms of p85 (Fig. 3C) may in part cause
the observed differences in ER activation. However, the in-
crease in ER-mediated transcription in N2a cells caused by
the truncated form of p85 was no longer present in the
presence of the GSK3 inhibitors LiCl (Fig. 3D) and SB415286
(not shown).
The specific Akt inhibitor III (SH-6) (38), produced a de-
crease in the serine 9 inhibitory phosphorylation of GSK3
(Fig. 3E). In addition, SH-6 induced a dose-dependent in-
crease in ER-mediated transcription (Fig. 3F). In this exper-
iment we tested the effects of the GSK3 inhibitors LiCl (Fig.
3F) and SB415286 (not shown). Both inhibitors blocked the
effect of SH-6 on ER activity, suggesting that GSK3 mediates
the effect of Akt on ER-mediated transcription.
The activity of GSK3 is finely regulated in mammalian cells
through many signaling pathways. In the brain, the phos-
phorylation of serine 9 of GSK3 by Akt kinase is one of the
main mechanisms by which some extracellular factors, such
as IGF-I and nerve growth factor (34–36), reduce the con-
stitutive activity of GSK3. In the next set of experiments we
tested the potential effects of extracellular regulators of
PI3K/Akt pathway on the transcriptional activity of ERs.
We first analyzed the effect of E2 on Akt and GSK3
phosphorylation. As shown in Fig. 4A, E2 did not affect the
phosphorylation levels of Akt serine 473 or GSK3 serine 9.
Moreover, E2 did not affect the wortmannin-induced de-
crease in the phosphorylation levels of both kinases. We then
tested the ability of endogenous IGF-IR to regulate Akt and
GSK3 phosphorylation and ER-mediated transcription in
N2a cells. IGF-I treatment dose-dependently increased the
phosphorylation of Akt on serine 473 in a wortmannin-sensitive
manner (Fig. 4B). A similar effect was observed when we an-
alyzed the phosphorylation of serine 9 of GSK3 (Fig. 4B).
To assess whether IGF-I affects ER-mediated transcription,
N2a cells were transfected with the reporter plasmid and
treated with E2 and IGF-I alone or in combination. Treat-
ment with IGF-I induced a small, but significant, activation
of the reporter construct (20% of theE2 response) that was
not affected by wortmannin treatment (Fig. 4C). In contrast,
the addition of both hormones, E2 and IGF-I, produced a
smaller response than that observed in the presence of E2
alone (Fig. 4C). This inhibitory effect was no longer detected
in the presence of wortmannin (Fig. 4C).
Because N2a cells express low levels of IGF-IR (Fig. 4D),
we tested the effect of the overexpression of two different
forms of IGF-IR. The overexpression of IGFIRwt in N2a cells
had an inhibitory effect on E2-induced, ER-mediated tran-
scription. This effect was not detected when a kinase-dead
form of this receptor (IGFIR-KR) was transfected in N2a cells
(Fig. 4D).
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ER interacts with -catenin in N2a cells
In search of a possible mechanism of GSK3-mediated con-
trol of ER activity, we studied the subcellular localization
of both proteins. We performed immunofluorescence detec-
tion of both proteins using specific antibodies. ER staining
was mainly localized to the cell nucleus, whereas GSK3
appeared to be located in the cytoplasm (Fig. 5A). We also
analyzed the potential interaction of these two proteins in
FIG. 3. PI3K regulates ER-dependent transcription through GSK3 in N2a cells. A, N2a cells were cultured in medium containing 2% C/D FCS
for 24 h and treated with vehicle (C) or the PI3K inhibitor wortmannin (W; 100 nM) for 15 or 30 min. The phosphorylation of GSK3 in serine
9 was analyzed in cell lysates by Western blotting using a phosphospecific antibody (pGSK3; upper gel). Total GSK3 was used as a control
(GSK3; lower gel). Treatment with wortmannin produced a decrease in the phosphorylation of GSK3. B, N2a cells were transfected with
pTA-ERE-SEAP and 24 h latter treated with the PI3K inhibitor wortmannin (W; 20 or 100 nM) in the presence or absence of 10 mM LiCl (30-min
pretreatment). Forty-five minutes later, E2 (1 nM) was added to the medium for an additional 24 h. The graph shows the induction of reporter
activity in each situation normalized to transfection efficiency. Data are presented as the mean  SEM. Wortmannin induced a dose-dependent
increase in ER-mediated transcription. The GSK3 inhibitor LiCl blocked the effect of wortmannin. *, P  0.05 vs. E2 plus 100 nM W; ∧, P 
0.05 vs. E2 plus 20 nMW. C, Cells were cotransfected with pTA-ERE-SEAP and the expression plasmids for two different forms of p85 subunit
of PI3K: thewt sequence (p85wt) and themutant negative form (p85110). A group of cells was transfectedwith the empty vector (M). To confirm
overexpression of the wt and mutated forms of p85, cell lysates were analyzed using an antibody against the Flag antibody fused to both forms
of p85 (FLAG; upper gel) or an antibody against p85 (p85; second gel). In addition, the phosphorylation of GSK3 in serine 9 was analyzed using
a phosphospecific antibody (pGSK3; third gel). Total GSK3 was used as a control (GSK3; lower gel). The arrowheadmarks an unspecific band
detected by the FLAG antibody in N2a cells. M, Cells transfected with an empty vector; p85 wt, cells transfected with the expression plasmid
for the wt form of p85; p85 110, cells transfected with the expression plasmid for the mutated form of p85. Lower panel, pGSK3/GSK3 ratio.
Overexpression of the mutated form of p85 resulted in a significant decrease in the phosphorylation of GSK3. *, P  0.05 vs.mock-transfected
cells (M). D, Cells were cotransfected with pTA-ERE-SEAP and three different plasmids: an empty vector (Mock), the wt form (p85wt) of p85,
or themutated form (p85110) of p85. Twenty-four hours later, cells were pretreated with LiCl for 45min, thenwith E2 (1 nM) for an additional
24 h. The graph shows the induction of reporter activity in each situation normalized to transfection efficiency. Data are presented as themean
SEM. Overexpression of the mutated form of p85 (p85110) resulted in a significant increase in ER-mediated transcription compared with cells
overexpressing the wt form. The GSK3 inhibitor LiCl blocked the increase in ER-mediated transcription induced by the mutated form of p85.
*, P  0.05 vs. E2 in the absence of LiCl in the p85110-transfected group. E, N2a cells were cultured in medium containing 2% C/D FCS
for 24 h and treated with vehicle (C) or the Akt inhibitor SH-6 (5 M) for 15, 30, or 60 min. Phosphorylation of GSK3 in serine 9 was analyzed
using a phosphospecific antibody (pGSK3). Total GSK3 was used as a control (GSK3). The Akt inhibitor SH-6 reduced the phosphorylation
of GSK3. F, N2a cells were transfected with pTA-ERE-SEAP and 24 h later treated with the Akt inhibitor SH-6 (1 or 5 M) in the presence
or absence of 10 mM LiCl (30-min pretreatment). Forty-five minutes later, E2 (1 nM) was added to the medium for an additional 24 h. The
graph shows the induction of reporter activity in each situation normalized to transfection efficiency. Data are presented as the mean  SEM.
SH-6 induced a dose-dependent increase in ER-mediated transcription. The GSK3 inhibitor LiCl blocked the effect of SH-6. *, P  0.05 vs. the
E2- plus 5 M SH-6-treated group.
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N2a cells using immunoprecipitation. N2a cells were trans-
fected with ER- and GSK3 (wt and R85 mutated forms)-
overexpressing plasmids. After 48 h, cultures were lysed and
subjected to immunoprecipitation using antibodies against
ER and GSK3. The immunocomplexes were resolved by
Western blotting, and both proteins were detected using
specific antibodies. As shown in Fig. 5B for immunoprecipi-
tation using ER antibody, we were not able to detect GSK3
in the immunocomplexes (Fig. 5B, upper gel), although the
efficiency of the process was sufficient, as shown by the
presence of large amounts of ER (Fig. 5B, lower gel). We were
also unable to detect ER in the immunoprecipitates ob-
tained with the GSK3 antibody (not shown).
-Catenin is one of the most characterized mediators of
GSK3 actions in the nucleus. For this reason, we hypothe-
sized that this protein could be mediating GSK3 actions on
ER activity. The stability of -catenin is controlled by GSK3
in the context of a multimolecular complex that includes
FIG. 4. IGF-I increases ER-dependent transcription in the absence of
E2 and decreases ER-dependent transcription, through PI3K, in the
presence of E2. A, To evaluate weather E2 regulates Akt andGSK3
phosphorylation, N2a cells were cultured for 24 h in medium con-
taining 2% C/D FCS, pretreated with wortmannin (W; 100 nM) or its
vehicle for 30 min, and then treated for 0, 15, 30, or 60 min with 10
nM E2. The activity of the Akt/GSK3 pathway was evaluated in total
cell lysates by Western blotting using phosphospecific antibodies
against serine 473 of Akt (pAkt; upper gel) and against serine 9 of
GSK3 (pGSK3;middle gel). Total GSK3 (GSK3; lower gel) was used
as a loading control. B, To assess whether endogenous IGF-IR in N2a
cells regulates Akt andGSK3 phosphorylation, cells were cultured for
24 h inmedium containing 2%C/D FCS, pretreated with wortmannin
(W; 100 nM) or its vehicle for 45 min, then treated for 30 min with 0
[control (C)], 1, 10, or 100 nM IGF-I. The activity of the Akt/GSK3
pathway was evaluated in total cell lysates byWestern blotting using
phosphospecific antibodies against serine 473 of Akt (pAkt; upper gel)
and against serine 9 of GSK3 (pGSK3;middle gel). Total Akt (lower
gel) was used as a loading control. Treatment with IGF-I increased
phosphorylation of Akt and GSK3, and this effect was blocked by the
PI3K inhibitorwortmannin. C, To assesswhether endogenous IGF-IR
in N2a cells affects ER-mediated transcription, cells were transfected
with pTA-ERE-SEAP and treated with vehicle (C), E2 (1 nM), IGF-I
(100 nM), or E2 combinedwith IGF-I after 45min of wortmannin (W)
or vehicle pretreatment. Reporter activity was measured 24 h later
and is presented as the mean  SEM. Treatment with either IGF-I or
E2 alone resulted in a significant increase in reporter activity. In
contrast, combined treatment with IGF-I and E2 resulted in signif-
icantly lower reporter activity than treatment with E2 alone. Wort-
mannin enhanced ER-mediated transcription in cells treated with
E2 or with both E2 and IGF-I and prevented the inhibitory effect
of IGF-I on E2-induced, ER-mediated transcription. *, P  0.05 vs.
E2 alone; ∧, P 0.05 vs. E2 plus IGF-I;, P 0.05 vs. the control
group (C; the minimum significant difference test was applied in this
case). D, N2a cells were cotransfectedwith pTA-ERE-SEAP and three
different plasmids: an empty vector (Mock), the wt human IGF-IR
(IGFIRwt),andamutant,kinase-inactiveIGF-IR(IGFIR-KR).Twenty-
four hours after transfection, cells were treated with E2 (1 nM) or its
vehicle for an additional 24 h. SEAP activity was then quantified and
normalized to transfection efficiency. The results shown are themean
fold induction in each situation SEM. Overexpression of the wt form
of IGF-IR decreased E2-induced, ER-mediated transcription. In con-
trast, ER-mediated transcriptionwasunchanged by overexpression of
the kinase-inactive form of IGF-IR. *, P  0.05 vs. E2 response in
empty vector (Mock)-transfected group. The level of IGF-IR in each
situation, as evaluated by Western blotting, is shown below.
FIG. 5. ER andGSK3 do not interact inN2a cells. A,N2a cellswere
cultured on gelatin-coated coverslips and in medium containing 2%
C/D FCS for 24 h. Cultures were fixed and processed for the immu-
nodetection of ER and GSK3. The signal from the Alexa Red 568-
conjugated secondary antibodywas analyzed in a confocalmicroscope.
Representative photographs are shown. ER immunoreactivity was
mainly nuclear, whereas GSK3 immunoreactivity was located in the
cytoplasm. Scale bar, 10 m. B, N2a cells were transfected with over-
expression plasmids for ER and two forms of GSK3 (GSK3wt and
GSK3R85) in the combinations described in the lower part of the figure.
Cell lysates were immunoprecipitated with an antibody against ER,
and the immunoprecipitates were subjected to Western blotting using
antibodies against GSK3 (GSK3; upper gel) and ER (lower gel). Lys
(10%), lanes loaded with 10% the immunoprecipitation input reveal the
presence of endogenous GSK3. Neither endogenous nor transfected
forms ofGSK3were detected in the immunoprecipitates. The detection
of large amounts of ER in the immunoprecipitates confirms the effi-
ciency of the immunoprecipitation.
Mendez and Garcia-Segura • PI3K and GSK3 Regulate ER Activity Endocrinology, June 2006, 147(6):3027–3039 3033
adenomatous polyposis coli and axin (39). In N2a cells, PI3K
and GSK3 activities control-catenin levels in opposite ways.
Western blotting analysis showed that blockade of PI3K with
wortmannin lowered the -catenin cellular content within
12 h (Fig. 6A, upper panel); in contrast, pharmacological in-
hibition of GSK3 (SB415286, 12 h) induced a robust increase
in -catenin expression (Fig. 6A, lower panel). The subcellular
distribution of -catenin was also affected by these treat-
ments, as detected by immunofluorescence analysis of
treated cells. GSK3 inhibition with SB415286 resulted in an
increase in the nuclear localization of -catenin, whereas this
effect was not detectable in wortmannin-treated cells (Fig.
6B). In search of a possible mechanism of GSK3-mediated
control of ER transcriptional activity, we assessed whether
ER and -catenin interact in our cellular model. We de-
tected colocalization of ER and -catenin in the cell nucleus
of N2a cells. This colocalization was strongly increased by the
GSK3 inhibitor SB415286 (Fig. 6B). In addition, an interaction
between ER and -catenin in N2a cells was detected in
immunoprecipitation experiments (Fig. 6C, upper panel). We
also observed that this interaction could be modulated if E2
was present in the immunoprecipitation buffer (Fig. 6C, lower
panel). We then assessed whether treatment of N2a cells with
E2 or PI3K and GSK3 inhibitors regulated this interaction.
With this aim, we performed immunoprecipitation in cells
treated for various periods of time with E2, wortmannin,
and SB415286. The interaction between ER and -catenin
was lowered to minimal levels after 45 min of E2 treatment
(Fig. 6D, left panel), returned to control values 1 h after ad-
dition of the hormone (Fig. 6D, left panel), and remained at
basal levels 24 h after hormone treatment (Fig. 6D, second
panel). The inhibition of PI3K with wortmannin also induced
a decrease in the interaction between ER and -catenin that
was detectable 1 and 10 h after the beginning of treatment
(Fig. 6D, third panel). In contrast, inhibition of GSK3 with
SB415286 induced an increase in the levels of -catenin as-
sociated with ER that were evident after 15 min of SB415286
treatment (Fig. 6D, right panel).
To test the role of -catenin in the regulation that the
PI3K/GSK3 pathway exerts on ER-mediated transcription,
we used a mutant, nondegradable form of this protein in
combination with reporter gene experiments. The mutation
of serine 33 to a tyrosine (-catenin S33Y) blocks GSK3 phos-
phorylation of this residue and thus prevents proteasome-
dependent -catenin degradation (23) and results in higher
expression levels than the wild-type form (assessed by West-
ern blotting; not shown). Probably as a consequence of this,
the levels of ER associated with the nondegradable mutant
of -catenin were also higher (Fig. 6E). Overexpression of the
mutated form of -catenin resulted in a similar induction of
ER-mediated transcription as overexpression of the wt form.
However, wortmannin did not enhance ER transcriptional
activity in cells overexpressing mutant -catenin, an effect
that was evident in cells expressing wt -catenin (Fig. 6F).
The PI3K/GSK3 pathway may regulate ER stability in
N2a cells
In search of a possible mechanism for the control that PI3K
and GSK3 exert on ER-mediated gene expression, we as-
sessed whether these kinases regulate the expression of ER
protein in N2a cells. In this experiment we tested the effects
of the three pharmacological inhibitors of GSK3 (LiCl, so-
dium valproate, and SB415286), and none of them nor over-
expression of the wt or mutated form of this kinase affected
the levels of endogenous ER protein in N2a cells (Fig. 7A).
We then analyzed the potential role of GSK3 in the regulation
of ER protein stability. To explore this possibility, N2a cells
were plated, transfected with a plasmid constitutively ex-
pressing human ER, and incubated in medium containing
2% C/D FCS for 24 h. The levels of ER recombinant protein
were evaluated by Western blotting at different times after
pharmacological blockade of GSK3 or PI3K. Wortmannin
induced a significant decrease in ER expression, reaching
46  1% of control levels after 6 h of treatment (Fig. 7B).
Conversely, the GSK3 inhibitor SB415286 produced a signif-
icant increase in ER protein expression, reaching 180 18%
of control levels 12 h after the initiation of treatment (Fig. 7B).
The ability of these inhibitors to regulate ER protein levels
was also evident when they were coadministered with the ER
antagonist ICI182780. This ER antagonist induced a rapid
degradation of ER (Fig. 7C, f). Wortmannin increased the
rate at which this degradation occurred, whereas GSK3 in-
hibition with SB415286 decreased it (Fig. 7C). To determine
the effect of ER protein stabilization on its transcriptional
activity, we performed reporter gene experiments in the
presence of MG132, a pharmacological inhibitor of the pro-
teasome. Low concentrations (1 m) of this compound se-
lectively blocked ER-mediated transcription in N2a cells (Fig.
7D).
Discussion
The results presented in this report show a new mecha-
nism by which intracellular kinase signaling pathways may
regulate gene expression. We used N2a cells as a model for
estrogen actions in neural cells. As observed for many neu-
rons in the rodent brain (3), these neuroblastoma cells ex-
press functional ER. In our experiments, the activation of
this subtype of ER is responsible for the majority of activation
of the ER construct.
In contrast to what happens in other cell types (17), phar-
macological inhibition of different members of the MAPK
cascade, one of the main IGF-IR signaling pathways, has no
significant effect on the E2-induced activity of ER in N2a
cells. However, our results show evidence of the control that
GSK3, one of the main effectors of the PI3K pathway, exerts
on ER-mediated transcription in neuronal cells. Pharmaco-
logical inhibition of GSK3 decreased E2-induced ER tran-
scriptional activity, suggesting that the activity of this kinase
positively regulates the activity of the endogenous ER in N2a
neuroblastoma cells. We used three different inhibitors, and
all of them resulted in a decrease in ER-mediated transcrip-
tion in a dose-dependent manner. LiCl and valproate did so
in a concentration range consistent with their EC50 values for
GSK3 inhibition (1 mm for LiCl and 2 mm for valproate). For
SB415286, the concentrations tested were higher than the
inhibitory constant for GSK3 (31 nm). These concentrations
were needed to block other GSK3-mediated effects on cor-
tical neurons (40), N2a cells (41), and a liver-derived cell line
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FIG. 6. -Catenin interacts with ER in N2a cells. A, N2a cells were cultured for 24 h in medium containing 2% C/D FCS, then treated with
the PI3K inhibitor wortmannin (W; 100 nM) or the GSK3 inhibitor SB415286 (SB; 25 M) for 12 h. The levels of -catenin (Cat; upper gels)
were evaluated byWestern blotting in total lysates obtained from these cultures; p85 was used as a loading control (lower gels). A representative
blot of three performed is shown. -Catenin levels were decreased by the PI3K inhibitor wortmannin and were increased by the GSK3 inhibitor
SB415286. B, Immunofluorescence analysis of -catenin and ER immunoreactivities in N2a cells. Cells were cultured in gelatin-coated
coverslips in 2%C/DFCS for 24 h. Cultures were then treatedwith 100 nMwortmannin, 25MSB415286, or its vehicle (control) for an additional
12 h. Cultures were fixed, and ER and -catenin (-cat) were detected using specific primary antibodies. The secondary antibodies were labeled
withAlexaRed 568 for ER andAlexaGreen 488 for-catenin. Representative photographs are shown.GSK3 inhibitionwith SB415286 resulted
in an increase in nuclear localization of -catenin and increased colocalization of -catenin with ER in the cell nucleus. This effect was not
detectable in wortmannin-treated cells. Scale bar, 10 m. C, Interaction between ER and -catenin in N2a cells in immunoprecipitation
experiments. Upper panel, N2a cells were transfected with pHEGO and cultured for 24 h in 2% C/D FCS. Aliquots containing 300 g protein
were subjected to immunoprecipitation using an ER-specific antibody or a nonrelated IgG (n.r.). The immunocomplexes were separated by
electrophoresis and transferred to membranes where -catenin was detected (Cat; upper gel). Ten percent of the immunoprecipitation input
was subjected to Western blotting to verify the efficiency of the process (lane Lys 10%). In the same membranes, ERwas also immunodetected
(lower gel). Lower panel, Cell lysates were subjected to immunoprecipitation with an ER antibody in the presence of 100 nM E2 or its vehicle
in the immunoprecipitation buffer. The immunocomplexes were resolved and probed for the presence of -catenin (Cat; upper gel) and ER
(lower gel). Representative gels are shown. The presence of E2 in the immunoprecipitation buffer decreased the amount of immunoprecipitated
-catenin. D, Effect of E2 treatment on the interaction of ER and -catenin. N2a cells were cultured, transfected with pHEGO, and treated
with E2, wortmannin (W; 100 nM), or SB415286 (SB; 25 M) for the indicated periods of time before lysis. Cell lysates were subjected to
immunoprecipitation andWestern blotting as described in C. Representative gels from three runs performed are shown. Left panel, A transient
decrease in the amount of immunoprecipitated -catenin was detected 45 min after the addition of E2 to the cultures. Immunoprecipitated
-catenin levels returned to control values 1 h after addition of hormone (left panel) and remained at control levels 24 h after treatment (second
panel). Third panel, Inhibition of PI3K with wortmannin induced a decrease in the interaction between ER and -catenin that was detectable
1 and 10 h after the beginning of treatment. Right panel, A rapid increase in the level of -catenin associated with ER was detected after
inhibition of GSK3 with SB415286. E, ER interaction with mutant -catenin. N2a cells were cotransfected with the expression plasmid for
ER and the expression plasmids for wt -catenin (wt) or a mutated, nondegradable form (S33Y). Cell lysates were subjected to immunopre-
cipitation and Western blotting as described in C. Representative gels from two runs are shown. Interaction between ER and both forms of
-catenin was observed. Indeed, the mutated form showed a stronger interaction with ER than the wt form. F, Cells were cotransfected with
pTA-ERE-SEAP and the expression plasmids for empty vector (Mock), wt -catenin (Cat wt), or themutated, nondegradable form (Cat S33Y).
Cells were then pretreated with 100 nM wortmannin (W) or its vehicle before the addition of 1 nM E2 for 24 h. SEAP activity was quantified
and normalized to transfection efficiency. The results are the mean fold induction in each situation  SEM. The PI3K inhibitor wortmannin
enhanced ER-mediated transcription in cells overexpressing wt -catenin. In contrast, wortmannin did not affect ER-mediated transcription
in cells overexpressing the nondegradable form of -catenin. *, P  0.05 vs. E2 in the Cat wt group.
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(32). The different concentrations of SB415286 needed to in-
hibit GSK3 activity in vitro and to block GSK3 effects in cells
may reflect the partial cell permeability of this compound. In
particular, it is possible that SB415286 may have restricted
access to the nuclear compartment, where it may exert its
effects on transcription. In addition, it should be noted that
the inhibitors used in this study are not fully specific for
GSK3. At the concentration used in our experiments, impor-
tant targets, such as inositol monophosphatase for LiCl (42)
and -aminobutyric acid (43) or histone deacetylases (44) for
valproate could be partially responsible for the effects on
ER-mediated transcription in N2a cells. We cannot exclude
that these additional actions of valproate and LiCl may be
involved in the different effects of the three inhibitors on
ER-mediated transcription in HEK293 cells and on RAR-
mediated transcription in N2a cells. Nevertheless, the only
known shared target of LiCl, valproate, and SB415286 is
GSK3, suggesting that this kinase is mediating the analogous
effects of these compounds on ER-mediated transcription in
N2a cells. A role for GSK3 in the regulation of ER-mediated
transcription is also suggested by the increased transcrip-
tional activity observed after overexpression of GSK3 in N2a
cells. The significant increase in ER activity (40%) induced
by GSK3 transfection was not insubstantial considering the
high endogenous basal levels of expression of GSK3 in N2a
cells. Furthermore, the enhancement of ER-mediated tran-
scription was not observed when a mutated, kinase-inactive
form of GSK3 (GSK3R85) (22) was transfected, suggesting
the possible involvement of GSK3 in the regulation of ER
activity.
Surprisingly, the transcriptional activity of RAR in N2a
cells was not inhibited by any of the three GSK3 inhibitors
used in our study. Moreover, treatment with LiCl and
SB415286 stimulated the response of the RAR-sensitive con-
struct. This suggests that the effect of GSK3 is specific for ER
and different from its effect on the activities of other members
of the superfamily of nuclear receptors to which both ER and
RAR belong. Interestingly, this same phenomenon has been
described for Akt in the control of these two nuclear receptors
(16). In addition, the control exerted by GSK3 on ER-medi-
ated transcription is also cell type dependent, because the
inhibition of ER activity by GSK3 blockade was not present
in HEK293 cells. Indeed, two of the GSK3 inhibitors used,
FIG. 7. The PI3K/GSK3 pathway regulates ER protein stability. A,
N2a cells were treated for 24 h with 20 mM LiCl (Li), 3 mM sodium
valproate (Valp), 25 M SB415286 (SB), and 100 nM wortmannin (W)
or transfected (TF) for 48 hwith wt GSK3,mutant GSK3 (GSK3R85),
or an empty vector (V). None of these treatments affected the level of
endogenous ER in N2a cells, evaluated by Western blotting with a
specific antibody against mouse ER (MC20). III-Tubulin (Tub) was
used as a loading control. B, N2a cells were transfected with expres-
sion plasmids for human ER (pHEGO), cultured for 24 h in medium
containing 2%C/DFCS, and treatedwith vehicle (C), wortmannin (W;
100 nM), or SB415286 (SB; 25 M) for 0, 1, 6, or 12 h. Levels of
recombinant ER were evaluated by Western blotting using an an-
tibody that recognizes human ER. III-Tubulin (Tub) was used as
a loading control. Data are the mean SEM. A significant decrease in
ER protein expression was detected 6 h after treatment with the
PI3K inhibitor wortmannin. In contrast, treatment with the GSK3
inhibitor resulted in a significant increase in ER protein expression
12 h after the addition of SB415286 to the cultures. *, P 0.05 vs. the
control group in each treatment. C, N2a cells were transfected as
described in B and preincubated for 1 h with 100 nMwortmannin (W),
25 M SB415286 (SB), or vehicle (V). Cells were then treated with the
ER antagonist ICI182780 (ICI; 200 nM) for 30 min, 1 h, or 2 h. ER
levels were evaluated as described in B and normalized to the level
of ER in each group at the beginning of ICI treatment (C). Data are
the mean  SEM. The ER antagonist induced a rapid degradation of
ER that was accelerated by wortmannin and delayed by the GSK3
inhibitor SB415286. *, P 0.05 vs. the control (V) at each time point;
∧, P 0.05 vs. SB415286-treated cells (SB) at each time point. D, N2a
cells were transfected with pTA-ERE-SEAP. Thirty minutes before
E2 addition, cultures were treated with the proteasome inhibitor
MG132 (MG; 1M) or its vehicle. Reporter activity was evaluated 24 h
later. Data, after normalization, are themean SEM. The proteasome
inhibitor MG132 blocked the induction of ER-mediated transcription
by E2. *, P  0.05 vs. the control (vehicles).
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LiCl and valproate, stimulate ER-mediated transcription in
HEK293 cells. Interestingly, IGF-I has a positive stimulatory
effect on ER-mediated transcription in this cell line (45).This
is in agreement with the tissue- and cell-specific effects de-
scribed for transcriptional effects of estrogen and could be
related to the differential recruitment of transcriptional co-
regulators in response to ER activation (46). A similar cell
type-specific effect of GSK3 in the control of nuclear receptor-
mediated transcription has been described previously for
androgen receptors (47, 48).
The Akt inhibitor SH-6 (38) and the PI3K inhibitor wort-
mannin induced a strong decrease in serine 9 phosphoryla-
tion of GSK3, suggesting that there is a functional link
among GSK3, Akt, and PI3K in N2a cells (36). Pharmaco-
logical or genetic inhibition of PI3K strengthened the re-
sponse of the estrogen-sensitive reporter construct. This sug-
gests that PI3K is a negative modulator of ER activity in N2a
cells, in contrast to what has been described in other cell types
(16, 49). Inhibition of GSK3 blocked the stimulatory effects of
Akt and PI3K inhibition on the transcriptional activity of ER
in N2a cells, indicating that changes in PI3K/Akt activities
are translated to changes in ER transcription by means of
GSK3. Our findings suggest that E2 is not interfering with
this mechanism, at least not by direct regulation of the ac-
tivity of the PI3K/Akt/GSK3 pathway, because Akt and
GSK3 phosphorylation is not affected by E2 treatment in
N2a cells. In contrast, the regulation of nuclear ER activity
by GSK3 could be elicited by extracellular treatment with
IGF-I or overexpression of IGF-IR in N2a cells. IGF-IR acti-
vation by ligand binding in the absence of E2 elicited a rapid
increase in Akt (serine 473) phosphorylation, a subtle in-
crease in GSK3 (serine 9) phosphorylation, and a delayed
increase in the activity of ER. The increase in ER activity
by IGF-I in N2a cells is similar in magnitude to that elicited
by IGF-I in other neuroblastoma cell lines (7). In addition, as
has been described for the effect of insulin in other neuro-
blastoma cells (50), the increase in ER activity induced by
IGF-I in the absence of E2 is independent of PI3K activity.
In contrast, when IGF-I was applied simultaneously with
E2, it reduced the response elicited by estrogen alone by
approximately 30%. This inhibitory effect of IGF-I was me-
diated by the PI3K pathway, as suggested by its blockade by
wortmannin treatment. Thus, in N2a cells, as in other cell
types (7, 50), IGF-I increases ER transcriptional activity in
the absence of E2. However, the effect of IGF-I is different
in the presence of E2. In this case, IGF-I decreases ER
transcriptional activity. Therefore, our results suggest that
the regulation of ER activity by IGF-I is different depending
on whether the ER ligand is present and that this differential
regulation of ER activity is possible in the same cell type.
The mechanisms involved in the regulation of transcrip-
tion factors by GSK3 are still unclear, but normally involve
direct phosphorylation (19). Because GSK3 and ER localize
to different cellular compartments in N2a cells, and we have
been unable to detect a direct interaction between these two
proteins (51), we hypothesized that GSK3 controls ER-
mediated transcription through an alternative mechanism.
Our findings suggest that the cross-talk between GSK3 and
ER is mediated by -catenin. The level of expression and the
nuclear localization of this protein in N2a cells are controlled
in opposite ways by PI3K and GSK3 activities. In addition,
this protein interacts with ER in a regulated manner in N2a
cells. Our results indicate that high levels of -catenin (total
and associated with ER) are negatively correlated with ER
transcriptional activity in N2a cells. Although the nonde-
gradable -catenin mutant (-catenin S33Y) had no effect on
ER transcription under basal conditions, its overexpression
completely blocked wortmannin-induced stimulation of
ERE-dependent activity. It is interesting to note that ER
showed greater interaction with the mutated form of -catenin
than with the wt form. It is tempting to speculate that the
increased binding of the mutated form of-catenin to ERmay
be involved in its inhibitory effect on wortmannin-induced
stimulation of ER activity. The role of the interaction with
-catenin on the transcriptional regulation by ER needs ad-
ditional investigation to be clarified, but our results suggest that
-catenin is part of the signaling pathway by which changes in
PI3K/GSK3 activity are translated into modifications of ER
transcriptional activity in N2a cells. The regulation of this in-
teraction by E2 raises the important question of the role of
transcription in the stability of the ER/-catenin complex. The
rapid down-regulation of the interaction between ER and
-catenin in N2a cells after E2 treatment, which is evident at
30–45 min, and the rapid recovery to control levels, which is
observed 1 h after hormone treatment, suggest that the de-
crease in stability of the ER/-catenin complex precedes the
first round of ER-mediated transcription (52). Therefore,
transcriptional activity is probably not involved in destabi-
lization of the ER/-catenin complex. An alternative pos-
sibility is that the decreased interaction between ER and
-catenin may represent an early event in the regulation of
ER-mediated transcription.
The convergence between -catenin and ER has been
demonstrated in other cell systems, but with different func-
tional outcomes (53). In the MCF-7 cell line, the overexpres-
sion of the -catenin S33Y mutant enhances ERE-mediated
transcription (53). This suggests a cell type specificity of
ER/-catenin interaction that, as we shown here and pre-
viously reported (54), is negatively regulated by E2 and has
an inhibitory role in ER-mediated transcription in neural
cells and tissue. In addition, in MCF-7 cells, the ER/-
catenin interaction has been shown to regulate the transcrip-
tional activities of both proteins (53). This reciprocal control
raises the possibility of a regulatory role of ER in -catenin-
mediated gene expression in neural cells.
Because degradation has emerged as an important regu-
latory mechanism governing the transcriptional activity of
ER, we decided to specifically explore the posttranscrip-
tional mechanism governing ER stability in N2a cells. The
experiments using plasmids constitutively expressing ER
allowed us to specifically study this aspect of ER protein
expression. Recent evidence shows that proteolysis is essen-
tial for ER-mediated transactivation, and that proteasome-
dependent turnover of ER is an integral characteristic of ER
activity (55). MG132, a proteasome inhibitor that interferes
with ER degradation (55), completely blocked ERE-medi-
ated gene expression in N2a cells. This suggests that there is
a functional link between ER degradation and activity in this
cell line also. Interestingly, the PI3K/GSK3 pathway seems
to affect the stability of unliganded, and antagonist-bound,
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recombinant ER in a manner compatible with this idea. The
GSK3 inhibitor SB415286, which blocked ER-mediated tran-
scription, induced a substantial increase in recombinant ER
protein levels, probably through the blockade of basal and
ICI182780-induced degradation of ER. In contrast, activa-
tion of GSK3 by wortmannin accelerated the degradation
rate, producing a decrease in ER protein levels. These re-
sults suggest that the mechanism by which the PI3K/GSK3
pathway regulates ER-mediated transcription includes the
control of ER proteolysis and turnover. This does not nec-
essarily imply that the PI3K/GSK3 pathway affects total ER
levels in the cells. Indeed, our findings indicate that the
expression levels of endogenous ER are independent of
PI3K and GSK3. This suggests that other cellular processes
regulating ER synthesis and degradation may be differen-
tially affected, directly or indirectly, by the PI3K/GSK3 path-
way to maintain stable levels of ER expression. Because the
levels of ER and -catenin are regulated in the same direc-
tion by PI3K and GSK3 activities in N2a cells, it is tempting
to speculate that the interaction between these two proteins
may be crucial for regulating ER proteolysis. The results
presented in this report are consistent with a protective role
of -catenin in ER proteolysis that may be responsible for
the inhibition of ER-mediated transcription. However, ad-
ditional studies are needed to clarify this point.
In summary, our results suggest that ER transcriptional
activity is regulated by intracellular kinases in N2a cells.
PI3K and Akt, through changes in GSK3 kinase activity, may
modulate ERE-dependent gene expression. This interaction
seems to be mediated by -catenin, which interacts in a
regulated manner with ER. In addition, PI3K and GSK3
activities regulate ER protein stability and antagonist-
induced degradation. Therefore, estrogen may be intimately
associated with kinase-signaling mechanisms in neuronal
cells. Through its interaction with GSK3, estrogen could be
regulating cytoskeleton dynamics, neuronal plasticity, and
neurodegenerative processes, all of which are targets of
GSK3 activity in neuronal cells (19). In addition, our results
represent a new mechanism by which extracellular factors
that regulate PI3K, Akt, and GSK3 activities could be affect-
ing the transcriptional activity of ERs. Thus, our findings
suggest that IGF-I decreases ER transcriptional activity in
N2a cells via the PI3K/Akt/GSK3 signaling pathway in the
presence of E2. In contrast, in full agreement with what has
been previously reported in other neuroblastoma cells (7, 50),
IGF-I increases the activity of the unliganded ER in N2a
cells by a mechanism that is not mediated by this signaling
pathway. Therefore, the regulation of ER transcriptional ac-
tivity by IGF-I may differ depending on the concentration of
E2. This dual mechanism may have many implications for
the physiological and pathological actions of IGF-I and E2
in the brain and other organs. However, additional studies
in other model systems are necessary to determine whether
this mechanism is applicable to other cell types and whether
it operates in the nervous system.
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